CEO Sees GLP-1 Drugs Hitting $50/Month

The current list price for popular GLP-1 drugs like Ozempic and Wegovy hovers around $1,000 to $1,350 for a month's supply without insurance. Eli Lilly's Mounjaro and Zepbound, which contain the active ingredient tirzepatide, have similar monthly list prices of approximately $1,080 to $1,086. Despite high list prices, manufacturer savings programs can dramatically lower costs for commercially insured patients, with some paying as little as $25 for a one- or three-month prescription. However, insurance coverage for weight loss indications is often limited, with one 2024 study showing only 34% of corporate plans covering GLP-1s for non-diabetic weight loss. The global market for GLP-1 drugs is projected to surge, with some analysts forecasting it could reach $150 billion to $200 billion by 2030. This growth is fueled by the increasing prevalence of obesity and diabetes, as well as the drugs' effectiveness. By 2030, it is estimated that approximately 25 to 30 million Americans will be on GLP-1 treatments. Major pharmaceutical companies are heavily invested in the GLP-1 space. Novo Nordisk, the maker of Ozempic and Wegovy, and Eli Lilly, which produces Mounjaro and Zepbound, are the current market leaders. However, other giants like Pfizer and Amgen are also developing their own GLP-1 therapies, signaling a future of increased competition. The comparison to the statin market is significant. The global statin market is expected to reach approximately $20.6 billion to $22.63 billion by 2032-2035. The introduction of generic versions of statins led to significant price reductions and wider adoption, a trajectory that many expect GLP-1s to follow. Several factors contribute to high drug prices, including research and development costs, patent protection that limits immediate competition, and a lack of price transparency among manufacturers, insurers, and pharmacy benefit managers. The pharmaceutical industry's significant lobbying efforts also play a role in shaping drug pricing policies. The future of GLP-1 pricing will be influenced by several key developments. The introduction of oral versions of these drugs, rather than injectables, is expected to increase usage. Furthermore, as patents for the initial wave of GLP-1 drugs expire, the entry of generic and biosimilar versions will be a critical factor in driving down costs. Efforts to make these drugs more affordable are already underway. Novo Nordisk has announced price reductions for some of its GLP-1 drugs, set to take effect in January 2027. Additionally, direct-to-consumer platforms and discount programs are offering cash-paying patients lower prices, with some monthly costs falling into the $149 to $349 range.